The Food & Drug Administration recently approved a drug, called empagliflozin, to help decrease the likelihood of heart-related death. Empagliflozin is used to control glucose in adults with type 2 diabetes. It works by blocking glucose from being absorbed by the body. It also helps get rid of glucose through urination. The approval for the new use came after a recent study of people with type 2 diabetes and heart disease. When empagliflozin or placebo was added to the standard of care, researchers reported a decreased risk for heart-related deaths. Side effects of emplagliflozin include dehydration.
Type 2 diabetes is a condition that affects the way the body uses glucose, or sugar. The body makes insulin to move glucose into its cells. In type 2 diabetes, the body may resist the effect of insulin or it may not produce enough insulin. Symptoms of type 2 diabetes include increased thirst and tiredness.